Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PRAMOD N NEHETE and KATHRYN SHELTON.
Connection Strength

1.483
  1. Effects of Transportation and Relocation on Immunologic Measures in Cynomolgus Macaques (Macaca fascicularis). J Am Assoc Lab Anim Sci. 2019 11 01; 58(6):774-782.
    View in: PubMed
    Score: 0.702
  2. Effects of transportation, relocation, and acclimation on phenotypes and functional characteristics of peripheral blood lymphocytes in rhesus monkeys (Macaca mulatta). PLoS One. 2017; 12(12):e0188694.
    View in: PubMed
    Score: 0.155
  3. Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques. J Control Release. 2024 02; 366:18-27.
    View in: PubMed
    Score: 0.059
  4. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates. Sci Transl Med. 2023 06 28; 15(702):eadg2887.
    View in: PubMed
    Score: 0.057
  5. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates. J Control Release. 2023 06; 358:116-127.
    View in: PubMed
    Score: 0.056
  6. Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats. Nat Commun. 2022 12 26; 13(1):7951.
    View in: PubMed
    Score: 0.055
  7. Extending drug release from implants via transcutaneous refilling with solid therapeutics. Adv Ther (Weinh). 2022 Feb; 5(2).
    View in: PubMed
    Score: 0.051
  8. Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates. Adv Ther (Weinh). 2021 Mar; 4(3).
    View in: PubMed
    Score: 0.048
  9. Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics. 2020 Oct 17; 12(10).
    View in: PubMed
    Score: 0.047
  10. Enhanced In Vivo Vascularization of 3D-Printed Cell Encapsulation Device Using Platelet-Rich Plasma and Mesenchymal Stem Cells. Adv Healthc Mater. 2020 10; 9(19):e2000670.
    View in: PubMed
    Score: 0.047
  11. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. Int J Pharm. 2020 Sep 25; 587:119623.
    View in: PubMed
    Score: 0.046
  12. Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. J Virol. 2019 05 15; 93(10).
    View in: PubMed
    Score: 0.043
  13. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release. 2018 09 28; 286:315-325.
    View in: PubMed
    Score: 0.040
  14. Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study. Biomed Microdevices. 2018 06 18; 20(2):49.
    View in: PubMed
    Score: 0.040
  15. Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques. PLoS One. 2017; 12(12):e0188807.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.